2-year results of YOSEMITE and RHINE: Faricimab remains noninferior to aflibercept with extended dosing schedule

Emily Kaiser, editor of Modern Retina™, sits down with Jennifer I. Lim, MD, FARVO, FASRS, to discuss her ARVO 2022 presentation, “Efficacy, durability, and safety of faricimab in diabetic macular edema: 2-year results from the phase 3 YOSEMITE and RHINE trials.” YOSEMITE and RHINE trials had previously shown noninferiority between faricimab and aflibercept for the treatment of diabetic macular edema (DME), and the 2-year results showed that up to 60% of patients could be dosed with faricimab every 16 weeks and 70% of patients could be dosed every 12 weeks following 4 loading doses.